Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy

References

• Dunlop AL, Wells JR. Approach to red eye for primary care practitioners. Prim Care. 2015 Sep;42(3):267–284.
   Google Scholar
• Caliskan B, Demir Y, Turkes C. Ophthalmic drugs: in vitro paraoxonase 1 inhibition and molecular docking studies. Biotechnol Appl Biochem. 2021;1:548
   Google Scholar
• Ackerman SL, Torkildsen GL, McLaurin E, et al. Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials. Clin Exp Optom. 2019 Mar;102(2):131–139.
   Google Scholar
• Azari AA, Barney NP. Conjunctivitis: a systematic review of diagnosis and treatment. Jama. 2013 Oct 23;310(16):1721–1729.
   Google Scholar
• Cronau H, Kankanala RR, Mauger T. Diagnosis and management of red eye in primary care. Am Fam Physician. 2010 Jan 15;81(2):137–144.
   Google Scholar
• Hosten LO, Snyder C. Over-the-counter ocular decongestants in the United States - mechanisms of action and clinical utility for management of ocular redness. Clin Optom (Auckl). 2020;12:95–105.
   Google Scholar
• Galor A, Jeng BH. Red eye for the internist: when to treat, when to refer. Cleve Clin J Med. 2008 Feb;75(2):137–144.
   Google Scholar
• Singh RB, Liu L, Yung A, et al. Ocular redness - II: progress in development of therapeutics for the management of conjunctival hyperemia. Ocul Surf. 2021 Jul;21:66–77.
   Google Scholar
• Abelson MB, Yamamoto GK, Allansmith MR. Effects of ocular decongestants. Arch Ophthalmol. 1980 May;98(5):856–858.
   Google Scholar
• Tappeiner C, Sarra GM, Abegg M. Abuse of vasoconstrictive eyedrops mimicking an ocular pemphigoid. Eur J Ophthalmol. 2009 Jan-Feb;19(1):129–132.
   Google Scholar
• Vaidyanathan S, Williamson P, Clearie K, et al. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med. 2010 Jul 1;182(1):19–24.
   Google Scholar
• Abelson MB, Butrus SI, Weston JH, et al. Tolerance and absence of rebound vasodilation following topical ocular decongestant usage. Ophthalmology. 1984 Nov;91(11):1364–1367.
   Google Scholar
• Fudemberg SJ, Batiste C, Katz LJ. Efficacy, safety, and current applications of brimonidine. Expert Opin Drug Saf. 2008 Nov;7(6):795–799.
   Google Scholar
• Norden RA. Effect of prophylactic brimonidine on bleeding complications and flap adherence after laser in situ keratomileusis. J Refract Surg. 2002 Jul-Aug;18(4):468–471.
   Google Scholar
• Desco MC, Navea A, Ferrer E, et al. Effect of prophylactic brimonidine on bleeding complications after cataract surgery. Eur J Ophthalmol. 2005 Mar-Apr;15(2):228–232.
   Google Scholar
• Hong S, Kim CY, Seong GJ, et al. Effect of prophylactic brimonidine instillation on bleeding during strabismus surgery in adults. Am J Ophthalmol. 2007 Sep;144(3):469–470.
   Google Scholar
• Ucar F, Cetinkaya S. The results of preoperative topical brimonidine usage in pterygium surgery. J Ocul Pharmacol Ther. 2020 May;36(4):234–237.
   Google Scholar
• Piwnica D, Rosignoli C, de Menonville ST, et al. Vasoconstriction and anti-inflammatory properties of the selective alpha-adrenergic receptor agonist brimonidine. J Dermatol Sci. 2014 Jul;75(1):49–54.
   Google Scholar
• Bertino B, Blanchet-Rethore S, Thibaut de Menonville S, et al. Brimonidine displays anti-inflammatory properties in the skin through the modulation of the vascular barrier function. Exp Dermatol. 2018 Dec;27(12):1378–1387.
   Google Scholar
• Docherty JR, Steinhoff M, Lorton D, et al. Multidisciplinary consideration of potential pathophysiologic mechanisms of paradoxical erythema with topical brimonidine therapy. Adv Ther. 2016 Nov;33(11):1885–1895.
   Google Scholar
• Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev. 2001 Jun;53(2):319–356.
   Google Scholar
• Angus JA, Cocks TM, Satoh K. The alpha adrenoceptors on endothelial cells. Fed Proc. 1986 Aug;45(9):2355–2359.
   Google Scholar
• Corboz MR, Rivelli MA, Mingo GG, et al. Mechanism of decongestant activity of alpha 2-adrenoceptor agonists. Pulm Pharmacol Ther. 2008;21(3):449–454.
   Google Scholar
• Mishra RC, Rahman MM, Davis MJ, et al. Alpha1 -adrenergic stimulation selectively enhances endothelium-mediated vasodilation in rat cremaster arteries. Physiol Rep. 2018 May;6(9):e13703.
   Google Scholar
• Sorriento D, Trimarco B, Iaccarino G. Adrenergic mechanism in the control of endothelial function. Transl Med UniSa. 2011 Sep;1:213–228.
   Google Scholar
• Demir Y. The behaviour of some antihypertension drugs on human serum paraoxonase-1: an important protector enzyme against atherosclerosis. J Pharm Pharmacol. 2019 Oct;71(10):1576–1583.
   Google Scholar
• Demir Y. Naphthoquinones, benzoquinones, and anthraquinones: molecular docking, ADME and inhibition studies on human serum paraoxonase-1 associated with cardiovascular diseases. Drug Dev Res. 2020 Aug;81(5):628–636.
   Google Scholar
• Singh RB, Liu L, Anchouche S, et al. Ocular redness - I: etiology, pathogenesis, and assessment of conjunctival hyperemia. Ocul Surf. 2021 Jul;21:134–144.
   Google Scholar
• Xu X, Zhang D, Zhang H, et al. Neutrophil histamine contributes to inflammation in mycoplasma pneumonia. J Exp Med. 2006 Dec 25;203(13):2907–2917.
   Google Scholar
• Leonardi A. Role of histamine in allergic conjunctivitis. Acta Ophthalmol Scand Suppl. 2000;230:18–21.
   Google Scholar
• Bielory L, Ghafoor S. Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol. 2005 Oct;5(5):437–440.
   Google Scholar
• Kirkegaard J, Secher C, Mygind N. Effect of the H1 antihistamine chlorpheniramine maleate on histamine-induced symptoms in the human conjunctiva. Indirect evidence for nervous H1 receptors. Allergy. 1982 Apr;37(3):203–208.
   Google Scholar
• Wade L, Bielory L, Rudner S. Ophthalmic antihistamines and H1-H4 receptors. Curr Opin Allergy Clin Immunol. 2012 Oct;12(5):510–516.
   Google Scholar
• Abelson MB, Udell IJ. H2-receptors in the human ocular surface. Arch Ophthalmol. 1981 Feb;99(2):302–304.
   Google Scholar
• Iversen PO, Nicolaysen A, Kvernebo K, et al. Human cytokines modulate arterial vascular tone via endothelial receptors. Pflugers Arch. 1999 Dec;439(1–2):93–100.
   Google Scholar
• Wilkinson MF, Earle ML, Triggle CR, et al. Interleukin-1beta, tumor necrosis factor-alpha, and LPS enhance calcium channel current in isolated vascular smooth muscle cells of rat tail artery. FASEB J. 1996 May;10(7):785–791.
   Google Scholar
• Brian JE Jr., Faraci FM. Tumor necrosis factor-alpha-induced dilatation of cerebral arterioles. Stroke. 1998 Feb;29(2):509–515.
   Google Scholar
• Cheranov SY, Jaggar JH. TNF-alpha dilates cerebral arteries via NAD(P)H oxidase-dependent Ca2+ spark activation. Am J Physiol Cell Physiol. 2006 Apr;290(4):C964–71.
   Google Scholar
• Brain SD, Williams TJ, Tippins JR, et al. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985 Jan 3-9;313(5997):54–56.
   Google Scholar
• Edvinsson L. Calcitonin gene-related peptide (CGRP) in cerebrovascular disease. ScientificWorldJournal. 2002 May 30;2:1484–1490.
   Google Scholar
• Wang Z, Martorell BC, Walchli T, et al. Calcitonin gene-related peptide (CGRP) receptors are important to maintain cerebrovascular reactivity in chronic hypertension. PLoS One. 2015;10(4):e0123697.
   Google Scholar
• Hirata Y, Takagi Y, Takata S, et al. Calcitonin gene-related peptide receptor in cultured vascular smooth muscle and endothelial cells. Biochem Biophys Res Commun. 1988 Mar 30;151(3):1113–1121.
   Google Scholar
• Suvas S. Role of substance P neuropeptide in inflammation, wound healing, and tissue homeostasis. J Immunol. 2017 Sep 1;199(5):1543–1552.
   Google Scholar
• Mashaghi A, Marmalidou A, Tehrani M, et al. Neuropeptide substance P and the immune response. Cell Mol Life Sci. 2016 Nov;73(22):4249–4264.
   Google Scholar
• Bignami F, Rama P, Ferrari G. Substance P and its inhibition in ocular inflammation. Curr Drug Targets. 2016;17(11):1265–1274.
   Google Scholar
• Steinhoff M, Schmelz M, Schauber J. Facial erythema of rosacea - aetiology, different pathophysiologies and treatment options. Acta Derm Venereol. 2016 Jun 15;96(5):579–586.
   Google Scholar
• Adkins JC, Balfour JA. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging. 1998 Mar;12(3):225–241.
   Google Scholar
• Caliskan B, Ozturk Kesebir A, Demir Y, et al. The effect of brimonidine and proparacaine on metabolic enzymes: glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, and glutathione reductase. Biotechnol Appl Biochem. 2022 Feb;69(1):281–288.
   Google Scholar
• Suzuki G, Kunikane E, Shinno K, et al. Ocular and systemic pharmacokinetics of brimonidine and timolol after topical administration in rabbits: comparison between fixed-combination and single drugs. Ophthalmol Ther. 2020 Mar;9(1):115–125.
   Google Scholar
• Kent AR, King L, Bartholomew LR. Vitreous concentration of topically applied brimonidine-purite 0.15%. J Ocul Pharmacol Ther. 2006 Aug;22(4):242–246.
   Google Scholar
• Takamura Y, Tomomatsu T, Matsumura T, et al. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans. J Ocul Pharmacol Ther. 2015 Jun;31(5):282–285.
   Google Scholar
• Jackson JM, Knuckles M, Minni JP, et al. The role of brimonidine tartrate gel in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2015;8:529–538.
   Google Scholar
• Okwundu N, Cline A, Feldman SR. Difference in vasoconstrictors: oxymetazoline vs. brimonidine. J Dermatolog Treat. 2021 Mar;32(2):137–143.
   Google Scholar
• Atlas D, Sabol SL. Interaction of clonidine and clonidine analogues with alpha-adrenergic receptors of neuroblastoma X glioma hybrid cells and rat brain: comparison of ligand binding with inhibition of adenylate cyclase. Eur J Biochem. 1981 Jan;113(3):521–529.
   Google Scholar
• Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother. 2000 May;1(4):815–834.
   Google Scholar
• Milligan G, Svoboda P, Brown CM. Why are there so many adrenoceptor subtypes? Biochem Pharmacol. 1994 Sep 15;48(6):1059–1071.
   Google Scholar
• Morrison JC. Side effects of alpha-adrenergic agonists. J Glaucoma. 1995 Feb;4:S36.
   Google Scholar
• Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995 Dec;113(12):1514–1517.
   Google Scholar
• Yoles E, Schwartz M. Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv Ophthalmol. 1998 Jan-Feb;42(4):367–372.
   Google Scholar
• Wheeler LA, Lai R, Woldemussie E. From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol. 1999 Jan-Mar;9:S17–21.
   Google Scholar
• Matsuo T, Cynader MS. Localization of alpha-2 adrenergic receptors in the human eye. Ophthalmic Res. 1992;24(4):213–219.
   Google Scholar
• Jonescu-Cuypers CP, Harris A, Ishii Y, et al. Effect of brimonidine tartrate on ocular hemodynamics in healthy volunteers. J Ocul Pharmacol Ther. 2001 Jun;17(3):199–205.
   Google Scholar
• Cambridge D. UK-14,304, a potent and selective alpha2-agonist for the characterisation of alpha-adrenoceptor subtypes. Eur J Pharmacol. 1981 Jul 10;72(4):413–415.
   Google Scholar
• Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology. 1997 Jan;104(1):131–136.
   Google Scholar
• Tuncer I, Bilgin S, Zengin MO, et al. Effect of brimonidine tartrate 0.15% on scotopic pupil size and upper eyelid position: controlled trial. Eye (Lond). 2021 Feb;35(2):672–675.
   Google Scholar
• McDonald JE 2nd, El-Moatassem KAM, Decker BB. Effect of brimonidine tartrate ophthalmic solution 0.2% on pupil size in normal eyes under different luminance conditions. J Cataract Refract Surg. 2001 Apr;27(4):560–564.
   Google Scholar
• Kesler A, Shemesh G, Rothkoff L, et al. Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size. J Cataract Refract Surg. 2004 Aug;30(8):1707–1710.
   Google Scholar
• Besada E, Reed K, Najman P, et al. Pupillometry study of brimonidine tartrate 0.2% and apraclonidine 0.5%. J Clin Pharmacol. 2011 Dec;51(12):1690–1695.
   Google Scholar
• Cate S, Bektas C, Turgut B. Comparative analysis of pupil diameters in light and dark conditions after instillation of 0.15% brimonidine drops in eyes with and without pseudoexfoliation syndrome. Beyoglu Eye J. 2020;5(3):209–213
   Google Scholar
• Nejad M, Lin SR, Hwang LH, et al. Effect of over-the-counter brimonidine tartrate 0.025% ophthalmic solution on pupil size in healthy adults. Graefes Arch Clin Exp Ophthalmol. 2021 Nov;259(11):3333–3338.
   Google Scholar
• Corboz MR, Varty LM, Rizzo CA, et al. Pharmacological characterization of alpha 2-adrenoceptor-mediated responses in pig nasal mucosa. Auton Autacoid Pharmacol. 2003 Aug;23(4):208–219.
   Google Scholar
• Corboz MR, Rivelli MA, Varty L, et al. Pharmacological characterization of postjunctional alpha-adrenoceptors in human nasal mucosa. Am J Rhinol. 2005 Sep-Oct;19(5):495–502.
   Google Scholar
• Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol. 1997 Jul;115(7):847–852.
   Google Scholar
• Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol. 1995 Jan;113(1):77–83.
   Google Scholar
• Inan UU, Ermis SS, Orman A, et al. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. J Ocul Pharmacol Ther. 2004 Aug;20(4):293–310.
   Google Scholar
• Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol. 1999 Jan;127(1):20–26.
   Google Scholar
• Spada CS, Nieves AL, Burke JA, et al. Differential effects of alpha-adrenoceptor agonists on human retinal microvessel diameter. J Ocul Pharmacol Ther. 2001 Jun;17(3):255–277.
   Google Scholar
• Bhandari A, Cioffi GA, Van Buskirk EM, et al. Effect of brimonidine on optic nerve blood flow in rabbits. Am J Ophthalmol. 1999 Nov;128(5):601–605.
   Google Scholar
• Carlsson AM, Chauhan BC, Lee AA, et al. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension. Am J Ophthalmol. 2000 Mar;129(3):297–301.
   Google Scholar
• Sastre M, Garcia-Sevilla JA. Density of alpha-2A adrenoceptors and Gi proteins in the human brain: ratio of high-affinity agonist sites to antagonist sites and effect of age. J Pharmacol Exp Ther. 1994 Jun;269(3):1062–1072.
   Google Scholar
• Chien DS, Homsy JJ, Gluchowski C, et al. Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes. Curr Eye Res. 1990 Nov;9(11):1051–1059.
   Google Scholar
• Acheampong AA, Shackleton M, Tang-Liu DD. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos. 1995 Jul;23(7):708–712.
   Google Scholar
• Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol. 1996 Nov;41(Suppl 1):S9–18.
   Google Scholar
• Robin AL. The role of alpha-agonists in glaucoma therapy. Curr Opin Ophthalmol. 1997 Apr;8(2):42–49.
   Google Scholar
• Thompson CD, Macdonald TL, Garst ME, et al. Mechanisms of adrenergic agonist induced allergy bioactivation and antigen formation. Exp Eye Res. 1997 May;64(5):767–773.
   Google Scholar
• Torkildsen GL, Sanfilippo CM, DeCory HH, et al. Evaluation of efficacy and safety of brimonidine tartrate ophthalmic solution, 0.025% for treatment of ocular redness. Curr Eye Res. 2018 Jan;43(1):43–51.
   Google Scholar
• McLaurin E, Cavet ME, Gomes PJ, et al. Brimonidine ophthalmic solution 0.025% for reduction of ocular redness: a randomized clinical trial. Optom Vis Sci. 2018 Mar;95(3):264–271.
   Google Scholar
• Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol. 1994 Jul;94(1):134–136.
   Google Scholar
• Soparkar CN, Wilhelmus KR, Koch DD, et al. Acute and chronic conjunctivitis due to over-the-counter ophthalmic decongestants. Arch Ophthalmol. 1997 Jan;115(1):34–38.
   Google Scholar
• Fratelli M, De Blasi A. Agonist-induced alpha 1-adrenergic receptor changes. Evidence for receptor sequestration. FEBS Lett. 1987 Feb 9;212(1):149–153.
   Google Scholar
• LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology. 1998 Oct;105(10):1960–1967.
   Google Scholar
• Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002 Apr;11(2):119–126.
   Google Scholar
• Lee DA, Gornbein J, Abrams C. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group. J Ocul Pharmacol Ther. 2000 Feb;16(1):3–18.
   Google Scholar
• Sztajnbok J. Failure of naloxone to reverse brimonidine-induced coma in an infant. J Pediatr. 2002 Apr;140(4):485–486.
   Google Scholar
• Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS. 2001 Oct;5(5):281–284.
   Google Scholar
• Berlin RJ, Lee UT, Samples JR, et al. Ophthalmic drops causing coma in an infant. J Pediatr. 2001 Mar;138(3):441–443.
   Google Scholar
• Walters G, Taylor RH. Severe systemic toxicity caused by brimonidine drops in an infant with presumed juvenile xanthogranuloma. Eye (Lond). 1999 Dec;13(Pt 6):797–798.
   Google Scholar
• Carlsen JO, Zabriskie NA, Kwon YH, et al. Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol. 1999 Aug;128(2):255–256.
   Google Scholar
• Soto-Perez-de-Celis E, Skvirsky DO, Cisneros BG. Unintentional ingestion of brimonidine antiglaucoma drops: a case report and review of the literature. Pediatr Emerg Care. 2007 Sep;23(9):657–658.
   Google Scholar
• Lai Becker M, Huntington N, Woolf AD. Brimonidine tartrate poisoning in children: frequency, trends, and use of naloxone as an antidote. Pediatrics. 2009 Feb;123(2):e305–11.
   Google Scholar
• Al-Shahwan S, Al-Torbak AA, Turkmani S, et al. Side-effect profile of brimonidine tartrate in children. Ophthalmology. 2005 Dec;112(12):2143.
   Google Scholar
• Pasquali TA, Aufderheide A, Brinton JP, et al. Dilute brimonidine to improve patient comfort and subconjunctival hemorrhage after LASIK. J Refract Surg. 2013 Jul;29(7):469–475.
   Google Scholar
• Rodriguez-Galietero A, Martinez JV, Del Buey A, et al. Use of brimonidine before LASIK with femtosecond laser-created flaps for the correction of myopia: a contralateral eye study. J Refract Surg. 2010 Jan;26(1):28–32.
   Google Scholar
• Munoz G, Albarran-Diego C, Sakla HF, et al. Increased risk for flap dislocation with perioperative brimonidine use in femtosecond laser in situ keratomileusis. J Cataract Refract Surg. 2009 Aug;35(8):1338–1342.
   Google Scholar
• Dahlmann-Noor AH, Cosgrave E, Lowe S, et al. Brimonidine and apraclonidine as vasoconstrictors in adjustable strabismus surgery. J AAPOS. 2009 Apr;13(2):123–126.
   Google Scholar
• Ucar F, Cetinkaya S. The results of preoperative use of topical brimonidine in strabismus surgery. J Ocul Pharmacol Ther. 2021 May;37(4):230–235.
   Google Scholar
• Kim DH, Yang HK, Han SB, et al. Effect of topical brimonidine 0.15% on conjunctival injection after strabismus surgery in children. J Ophthalmol. 2021;2021:5574194.
   Google Scholar
• Kim CS, Nam KY, Kim JY. Effect of prophylactic topical brimonidine (0.15%) administration on the development of subconjunctival hemorrhage after intravitreal injection. Retina. 2011 Feb;31(2):389–392.
   Google Scholar
• Desco MC, Martin JCM, Mataix-Boronat J, et al. Prophylactic effect of brimonidine to minimize the incidence of subconjunctival hemorrhage in the early postoperative period after 23G pars plana vitrectomy. Ther Adv Ophthalmol. 2021 Jan-Dec;13:25158414211045753.
   Google Scholar